Immunoblotting patterns with Mycoplasma pneumoniae of serum specimens from infected and non-infected subjects

Aubert, Geraldine; Pozzetto, Bruno; Hafid, Jamal; Gaudin, O. G.

doi:10.1099/00222615-36-5-341

Cited by 7 publications

(6 citation statements)

References 13 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in other countries [16,17], the main exposure to M. pneumoniae in the Israeli population occurs during school age, resulting in at least 80% of adults having antibodies (Fig. 1).…”

Section: Agreement Of Performance Among Different Tests According Tomentioning

confidence: 67%

“…With the LISA IgG assay there was also a significant association between blood group B and positive or equivocal sera (63.4% of group B sera vs. 38.0% of other groups; p < 0.003). This association was also significant for unequivocally positive sera (26.8% of B group sera vs. 16.1% of other groups; p < 0.029). While this suggested that blood group B might produce some false-positive reactions with this kit, another explanation might be the cutoff calculation applied in this test, since the same association was not observed with the Immuno-Well IgG assay, which uses the same plates and reagents.…”

mentioning

confidence: 78%

See 1 more Smart Citation

Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection

Nir-Paz

Michael-Gayego

Ron

et al. 2006

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Eight commercially available tests for Mycoplasma pneumoniae (Serodia-Myco II, Labsystems IgM and IgG EIA, IgM and IgG LISA tests, ImmunoWell IgG test and SeroMP IgM and IgG) were compared using 204 single sera from healthy individuals. IgM peaked in late childhood and then declined, while IgG rose progressively into adulthood. Inter-assay agreement was poor. Positivity in Serodia-Myco II and LISA IgG was associated with blood group or Coombs positivity, suggesting non-specific reactions. The study confirmed that single serum serology is unsuitable for the diagnosis of M. pneumoniae infection, and that commercially available tests need further improvement.

show abstract

“…As in other countries [16,17], the main exposure to M. pneumoniae in the Israeli population occurs during school age, resulting in at least 80% of adults having antibodies (Fig. 1).…”

Section: Agreement Of Performance Among Different Tests According Tomentioning

confidence: 67%

mentioning

confidence: 78%

Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection

Nir-Paz

Michael-Gayego

Ron

et al. 2006

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…IgG seroconversion in M. pneumoniae infected patients is estimated to occur from 3 to 8 weeks following infection. EIAs are more sensitive than both the CF and MAG tests ( Moule et al, 1987 ; Aubert et al, 1992 ; Nir-Paz et al, 2006 ) for detecting acute infection. Most EIAs implement a 96 well-microtiter plate.…”

Section: Diagnosismentioning

confidence: 97%

A Compendium for Mycoplasma pneumoniae

2016

View full text Add to dashboard Cite

Historically, atypical pneumonia was a term used to describe an unusual presentation of pneumonia. Currently, it is used to describe the multitude of symptoms juxtaposing the classic symptoms found in cases of pneumococcal pneumonia. Specifically, atypical pneumonia is a syndrome resulting from a relatively common group of pathogens including Chlamydophila sp., and Mycoplasma pneumoniae. The incidence of M. pneumoniae pneumonia in adults is less than the burden experienced by children. Transmission rates among families indicate children may act as a reservoir and maintain contagiousness over a long period of time ranging from months to years. In adults, M. pneumoniae typically produces a mild, "walking" pneumonia and is considered to be one of the causes of persistent cough in patients. M. pneumoniae has also been shown to trigger the exacerbation of other lung diseases. It has been repeatedly detected in patients with bronchitis, asthma, chronic obstructive pulmonary disorder, and cystic fibrosis. Recent advances in technology allow for the rapid diagnosis of M. pneumoniae through the use of polymerase chain reaction or rapid antigen tests. With this, more effort has been afforded to identify the causative etiologic agent in all cases of pneumonia. However, previous practices, including the overprescribing of macrolide treatment in China and Japan, have created increased incidence of macrolide-resistant M. pneumoniae. Reports from these countries indicate that >85% of M. pneumoniae pneumonia pediatric cases are macrolide-resistant. Despite its extensively studied past, the smallest bacterial species still inspires some of the largest questions. The developments in microbiology, diagnostic features and techniques, epidemiology, treatment and vaccines, and upper respiratory conditions associated with M. pneumoniae in adult populations are included within this review.

show abstract

“…They determined that this PA test was not as specific for detection of IgM as the other tests. Aubert et al (14) felt that PA tests performed about as well as EIAs and IFAs, but Matas et al (286) reported the Meridian ImmunoCard EIA was able to detect lower levels of IgM antibodies than either the Serodia Myco II kit or CF tests. Karppelin et al (219) evaluated the Serofast (International Microbio, Toulon, France) and found it to be less sensitive than CF and EIA.…”

Section: Serologymentioning

confidence: 99%

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

2004

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a unique bacterium that does not always receive the attention it merits considering the number of illnesses it causes and the degree of morbidity associated with it in both children and adults. Serious infections requiring hospitalization, while rare, occur in both adults and children and may involve multiple organ systems. The severity of disease appears to be related to the degree to which the host immune response reacts to the infection. Extrapulmonary complications involving all of the major organ systems can occur in association with M. pneumoniae infection as a result of direct invasion and/or autoimmune response. The extrapulmonary manifestations are sometimes of greater severity and clinical importance than the primary respiratory infection. Evidence for this organism's contributory role in chronic lung conditions such as asthma is accumulating. Effective management of M. pneumoniae infections can usually be achieved with macrolides, tetracyclines, or fluoroquinolones. As more is learned about the pathogenesis and immune response elicited by M. pneumoniae, improvement in methods for diagnosis and prevention of disease due to this organism may occur

show abstract

Immunoblotting patterns with Mycoplasma pneumoniae of serum specimens from infected and non-infected subjects

Cited by 7 publications

References 13 publications

Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection

Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection

A Compendium for Mycoplasma pneumoniae

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

Contact Info

Product

Resources

About